Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
757.530.04%
QQQ
706.900.25%
BTC/USD
77143.890.7965%
DIA
520.830.02%
GLD
395.600.19%
TLT
80.750.04%

Tenaya Therapeutics Inc

TNYANASDAQ
Trade with Public
Trade with Public
$0.6488
-0.0122-1.85%
At close: Sep 10, 5:00 PM EST
$0.6490
0.00020.03%
After Hours: 7:55 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Tenaya Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Tenaya Therapeutics (TNYA).

Price Target Range — 10 Quarters

Analyst Consensus — 6 Analysts

6Buy
Consensus RatingBuy# Analysts6Avg. Consensus PT$6Upside to Avg. PT+762.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Mar 12, 2026Chardan CapitalGeulah LivshitsMaintainedBuy$8
Dec 18, 2025Canaccord GenuityWhitney IjemPT CutBuy$6→$5
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Tenaya Therapeutics, Lowers Price Target to $3

HC Wainwright & Co. analyst Joseph Pantginis maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and lowers the price target from $5 to $3.
Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on Tenaya Therapeutics, Lowers Price Target to $8

Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and lowers the price target from $9 to $8.
Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on Tenaya Therapeutics, Maintains $9 Price Target

Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $9 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $5 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $5 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $5 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $5 price target.
Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on Tenaya Therapeutics, Maintains $9 Price Target

Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $9 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved